Consistency across deliveries
Significant volume dropoffs from other vendors had made it difficult to rely on the data for ongoing lead generation.
Case study · Rare disease · LEMS
When every patient matters,
every signal needs to count.
How a biopharmaceutical company used timely, consistent lab-based HCP alerts to support commercialization of a therapy for Lambert-Eaton myasthenic syndrome.
ClientA biopharmaceutical company focused on a rare neuromuscular disorder
Therapeutic areaLambert-Eaton myasthenic syndrome (LEMS)
ProgramLab-based HCP alerts
14New patients attributed to the program in the first year
15:1Reported ROI based on first-year revenue
Same dayTypical field availability reported by the client
“Without doubt, the most impactful marketing lever that we can pull.”Client feedback
Published LEMS case study
The challenge
Rare patients.
No room for unreliable signals.
The client needed to identify relevant patient signals consistently and get useful alerts into the hands of the field team quickly.
Timeliness for field action
Alerts needed to move into the client’s systems promptly so the field team could incorporate them into its workflow.
Clinically specific testing
Distinguishing N-type from P/Q-type testing was important to the client’s LEMS patient-identification approach.
The importance of every patient
In a rare disease, each relevant patient signal matters. Clinical specificity and reliable delivery were central to the program’s value.
The Prognos solution
Clean data.
A shorter path to field action.
Prognos implemented a lab-based HCP alerts program focused on consistent delivery, clinically relevant detail, and practical integration into the client’s commercial workflow.
Direct lab partnership
Work directly with the lab to support the feed and address issues when they arose.
Consistent, useful records
Deliver clean alerts with test distinctions and permitted demographic details relevant to the program.
Salesforce opportunities
Load leads as opportunities in the client’s Salesforce system on the day they were provided.
Field prioritization
Use the alerts as a next-best-action input to help the field team prioritize call plans.
Clinical detail built into the feed.
The published program included patient year of birth and gender, alongside relevant testing information, to support the client’s permitted follow-up workflow.
Support when the data needed attention.
When a volume dip occurred, Prognos worked through its direct lab relationship to address the issue. The client recognized that hands-on support.
The impact
A program the team
could put to work.
The client reported an increase in patient volume after adding Prognos data, alongside greater confidence in data consistency and the field workflow.
The clinical signal became a practical input to commercial action.
Patient impact and reported return
The published case study attributes 14 new patients in the first year to the program and reports a 15:1 ROI based on that year’s revenue.
Reliable information for the field
Clean, consistent deliveries helped the client avoid the large count dropoffs experienced with other vendors. The client reported that data usually reached the field the same day.
A stronger basis for prioritization
The field force used the alerts as a next-best-action insight to help prioritize call plans and follow-up.
Confidence in the partnership
The client described the program as meeting its objectives, reported strong internal enthusiasm, and increased its investment in the alerts program.
Explore the approach for your team
Bring the clinical signal
into your rare disease strategy.
Start with the indication, patient profile, and HCP workflow you need to support.
Make the next relevant
signal easier to act on.
Talk with Prognos about clinically specific lab data, recurring alerts, and a delivery approach built around your team.